Given the selection and implications of R273-p53 mutations in cancer progression, it is imperative to understand and model clinically relevant p53-GOF mutations and not assume all mutations, even at the same residue, generate the same molecular and biological outcomes. The gene discussed is TP53; the disease is cancer.